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Abstract 
 The vacuolar-type H
+
-ATPases (V-ATPases) are abundant enzymes in the ruffled 
border of the osteoclast that have a fundamental role in the bone resorption process. 
Consequently are considered crucial therapeutic targets in the treatment of lytic bone diseases. 
In the present study, 80 mg of omeprazole, a gastric proton pump inhibitor (PPI), was 
evaluated in vivo, in calvarial critical size defects in Wistar rats, whether it increases bone 
regeneration when associated with the hydroxyapatite granules, Osteopatite
®
, and modified 
exoskeleton of shrimp (MES) membrane. In the same animal there were both test and control 
defects (paired sample design). Although the results show slightly more bone regeneration and 
more Osteopatite
® 
granules osseointegration in the test defects than in the controls, the results 
must be considered inconclusive. This issue will need further studies and to adequate the 
methodologies, in order to verify the omeprazole therapeutic effects as a potential local 
osteoclast function inhibitor. 
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Introduction 
Bone is a dynamic tissue that is continuously remodeling itself by a process called 
coupling, in which the oldest tissue is reabsorbed by the osteoclasts and new bone is formed by 
the osteoblasts in a coordinated and proportioned way. This process enables the repair of 
microdamage, maintenance of mature bone mass and quality, adaptation to the load placed upon 
it and calcium homeostasis [1-3]. 
The osteoclasts are large, highly movable, multinucleated cells derived from the fusion 
of hematopoietic mononuclear cells [4-6]. According to Xu et al. (2007) [4] resorption includes 
4 stages and begins with the osteoclast attachment to the calcified bone surface via actin 
microfilaments and αv3 integrins. Afterwards, it undergoes a cytoskeletal and membrane 
polarization dividing it into three parts: the basolateral membrane facing the marrow space and 
surrounding the basal side of the cell where are most of the organelles and nuclei, the tight 
sealing zone which is closely opposed to the bone matrix, the ruffled border with its cytoplasm 
protrusions and encircled by the clear zone that has no organelles [4,7,8]. Consequently, an 
isolated microcompartment forms (the Howship or resorption lacuna) between the bone and the 
ruffled border, where the resorption will take place [4,9].  
Since bone consists of inorganic (hydroxyapatite) and organic (mostly collagen type I) 
components, the next stage includes firstly an acidification phase that is a prerequisite for the 
proteolytic phase [3,9,10]. The osteoclast secretes hydrochloric acid thanks to numerous plasma 
membrane V-ATPases present on the ruffled border that actively extrude protons to the 
Howship lacuna, as well as chloride channels ClC-7 that diffuse passively Cl
-
 ions, maintaining 
the electrochemical gradients [1,4,3,7,9-11]. The proteolytic enzymes such as cathepsin K and 
matrix metalloproteinases require an acidic environment to degrade the exposed proteinaceous 
bone matrix [2-5,9-11]. The resultant products are transported via transcytotic carrier vesicles to 
the basal zone and released to the extracellular environment [4].  
Intracellular V-ATPases are a class of ATP-driven multisubunit proton pumps found in 
all eukaryotic cells [1,3,6], which are primarily responsible for the acidification of intracellular 
compartments of both constitutive and specialized secretory pathways [3-6,11], including cell 
differentiation, endocytosis, intracellular membrane traffic, macromolecular processing, 
neuronal transmission, degradation and ligand-coupled transport, cell invasion by viruses and 
tumor metastasis [4,8,11]. The V-ATPases in plasma membranes that face the extracellular 
environment specifically have been identified only in a few cell types like the osteoclast, the 
kidney‟s intercalated cells, the epididymus cells, neutrofils and macrophages [3,5,6,11]. 
Generally, V-ATPases are composed of at least 14 subunits and several accessory 
proteins. While the V1 domain (A to H subunits) carries out ATP hydrolysis, the V0 domain (a1 
to e2 subunits) anchors the complex to the membrane (especially through the a subunit) and 
translocates the protons [4-6,8]. In the osteoclast, the structures of the subunits have been shown 
to differ from those in other cells [12], and it contains a specific a3 subunit, responsible for 
severe osteopetrosis when there is loss of function [1,4,6,8]. 
Given the essential role of the V-ATPase in the osteoclast function, it becomes a 
fundamental therapeutic target [4,8,11,12] in the treatment of lytic bone diseases like 
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osteoporosis, bone aseptic loosening, tumor-induced bone destruction, Paget‟s disease or 
periodontitis [2,4,8]. Many drugs have already been studied as anti-resorptive agents (Table 1).  
 
Table 1. V-ATPases inhibitors 
V-ATPase Inhibitors  Acting targets Sources 
Bafilomycin A1  V0 a subunit  Streptomices species 
Concanamycin A  V0 c subunit Streptomices species 
SB 242784  Osteoclast V-ATPase Bafilomycin derivatives 
FR167356  Osteoclast V-ATPase Novel chemical structure 
Salicylihalamide A  V-ATPase Benzolactone enamide core structure 
Lobatamides  V-ATPase Benzolactone enamide core structure 
Oximidines  V-ATPase Benzolactone enamide core structure 
Destruxin B  V-ATPase Fungus Metarhisium anisopliae 
Omeprazole  Gastric H
+
/K
+
ATPase Thiol reagents 
Adapted from Xu et al. (2007) [4] 
 
The first specific V-ATPase inhibitor to be studied was bafilomycin A1, a macrolide 
antibiotic with a specific and potent inhibitory effect on all V-ATPases in vitro and in vivo 
[4,12]. It interferes with the proton transport by binding to subunit C of the V-ATPase [12]. 
However, being a nonspecific inhibitor of all V-ATPases, bafilomycin A1 could exhibit 
unacceptable levels of toxicity of the cellular physiology, thus making its use as a systemic anti-
resorptive agent unfeasible [2,4,11]. Therefore, for the treatment of excess bone resorption, it is 
necessary to modify the structure of bafilomycin A1 to confer higher selectivity for the 
osteoclast V-ATPase enzyme [4]. Since 1998 that Gagliardi and his investigation group [11] 
have been trying to synthesize a drug as potent as bafilomycin A1, but selective to the 
osteoclasts‟ V-ATPases and, consequently, not as toxic. The same investigators came up in 
2000 [13] with a derivative of bafilomycin A1, SB 242784, which was subsequently 
investigated in 2001 [14] and 2002 [15], reporting that it prevented bone loss in ovariectomized 
rats [13] and it showed osteoclast V-ATPase selective inhibition [14]. In 2005 Niikura et al. [2] 
compared a novel osteoclast V-ATPase inhibitor, FR167356, with bafilomycin A1 and SB 
242784 in vitro and in vivo and concluded that it might be more appropriate for clinical 
application. Moreover, in another 2005 study, Niikura et al. [16] prevented alveolar bone 
destruction in experimental periodontitis in rats with oral administration of FR167356. In 
addition, in 2007, Sørensen et al. [1] studied a natural compound, diphyllin, as a novel inhibitor 
of the human osteoclast V-ATPase, concluding that it strongly inhibited acidification of the 
lysosomes and the resorption lacunae. However, in all of these experiments the drugs were 
studied having in mind a systemic approach of their potential applications, especially for the 
treatment of osteoporosis. The only exception goes to an experiment by Rzeszutek et al. (2003) 
[12], where bafilomycin A1 was incorporated in the chemical composition of calcium phosphate 
rods, which were implanted in vivo in osseous defects, to observe the local effect of the PPI on 
the rods resorption by the osteoclasts. They ended not only with a slower resorption of the graft 
material but also of the newly formed bone.  
Omeprazole is a selective and irreversible inhibitor of the gastric parietal cells‟ 
H
+
/K
+
ATPases and is currently used to treat peptic ulcer, Helicobacter pylori infection, 
gastroesophageal reflux disease, non-steroidal anti-inflammatory drug-induced gastrointestinal 
4 
 
lesions and Zollinger-Ellison syndrome [17]. It was the first gastric PPI to be introduced in the 
pharmaceutical market in 1989 and since then it has demonstrated an excellent safety profile for 
long-term use [17]. It is generally well tolerated, even by pregnant women and children, and the 
incidence of adverse effects is relatively low, approximately 1-3% [17,18]. In the active parietal 
cells‟ acidic environment it converts to the active cationic sulfonamide that binds to the 
H
+
/K
+
ATPase‟s α subunit, thus inhibiting acid secretion up to 36 hours [17,19].  
Although the gastric proton pump is different from the osteoclast‟s V-ATPase, in vitro 
and in vivo studies have demonstrated that omeprazole inhibits systemic bone resorption [19]. 
Back in 1986, Tuukkanen and Väänänen [20] cited a demonstration of immunological cross-
reactivity between the gastric H
+
/K
+
ATPase and “proteins” from the osteoclast ruffled border 
(later on named V-ATPase) in rats. As a consequence, they performed an experiment in vitro, 
where they demonstrated that both the basal resorption of mouse calvarial bones and their 
prostaglandin or parathyroid (PTH) stimulated resorption could be inhibited by doses of 
omeprazole sufficient to block the gastric acid secretion in vitro. However, in 1990 Väänänen et 
al. [19] did not find any immunoreactions in osteoclasts when antibodies against gastric 
H
+
/K
+
ATPase were used. 
The aim of this preliminary study is to evaluate if the hydroxyapatite granules, 
Osteopatite
®, and MES membrane‟s bone regeneration capacity increases when associated with 
a PPI like omeprazole, in rat calvarial critical size defects.  
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Materials and methods 
 
Hydroxyapatite granules 
In this study it was used Osteopatite
®
 granules, which can be considered a modified 
hydroxyapatite, developed at the Institute of Biomedical Engineering (INEB) at the University 
of Oporto. The basic apatite formula Ca10(PO4)6(OH)2 is chemically altered by the addition of 
usual bone cations such as Fe
3+
, Mg
2+
, Na
2+
 and K
+
, which partially substitute the cation 
Ca
2+
.The chemical composition of Osteopatite
®
 by weight is summarized at Table 2 and it 
matches that of bone natural hydroxyapatite [21]. The granules of Osteopatite
®
 are microporous, 
presenting a granule size of -20/+ 100 mesh (ASTM) (0.15-0.85 mm) [21] (Figure 1). 
 
Table 2. Chemical composition of Osteopatite
®
 by weight 
Chemical compound % w/w 
P2O5 43,1 
K2O 1,0 
Al2O3 0,21 
CaO Residual 
MgO 0,7 
Na
2
O 3,1 
Fe2O3 0,34 
Adapted from Vasconcelos et al. (1997) [21] 
 
 
 
 
 
 
 
 
 
 
 MES Membrane 
Chitin is a linear beta 1,4-linked polymer of N-acetyl-D-glucosamine (GlcNAc) and is 
the second most abundant biopolymer in nature, which is extracted primarily from the 
Fig. 1. Osteopatite
®
 granules 
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exoskeleton of crustaceans, but also from insects and fungi [22]. In the last 40 years it has 
aroused the interest of the scientific community for its potential biomedical applications as a 
dressing material, drug delivery vehicle and, increasingly, a candidate for tissue engineering 
[23]. The reasons are its versatile biological activity, excellent biocompatibility and complete 
biodegradability in combination with low toxicity [22]. 
In order to fix the Osteopatite
®
 granules and to increase the osseous regeneration it was 
used MES membranes from the shrimp´s chitin exoskeleton (Palaemonetes spp.), which were 
also developed at INEB (Figure 2). The crustaceans are from the Atlantic ocean weighted 
between 12,5 and 17,0 g. The exoskeleton was detached from the abdomen and washed in a 
sonicated NaOH 3% (w/w) solution at 70º C in order to remove its proteins. This solution was 
substituted 10 times, until the exoskeletons looked white and then were washed with distilled 
water to remove the NaOH residues. Afterwards, the samples were superficially modified by 
immersing in a sodium silicate 25% (w/w) solution for 1 hour and drying, so as to add silicon to 
its composition. This superficial treatment allows the formation of an apatite layer on the 
membranes surface after immersion in a simulated body fluid at 37º C, where Ca was 
substituted for Sr (SBF-Sr) (composition on Table 3) for one week [24]. Just before its surgical 
application, the MES membranes were boiled until sterilization and were stored in a saline 
solution. 
 
 
 
 
 
 
 
 
 
Table 3. Chemical composition of SBF-Sr (pH 7) 
Chemical compound mmol/L 
NaCl 136,8 
NaHCO3 4,2 
KCl 3 
KHPO4 3 
H2O 1 
MgCl2 6 
Na2SO4 0,5 
SrCl2 2,5 
HCl 1 M 
Adapted from Mesquita et al. (2004) [24] 
 
Fig. 2. Boiled MES membrane 
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Omeprazole 
 The pharmaceutical form of the omeprazole (Laboratórios BIAL - Portela & Cª SA, S. 
Mamede do Coronado, Portugal) used was powder (Figure 3). Omeprazol was stored in a plastic 
bottle at 4º C. 80 mg ± 0,1 mg of omeprazol for each test defect were weighted using an 
analytical balance (Kern
®
 770-13, Kern & Sohn GmbH, Balingen, Germany). 
 
 
 
 
 
 
 
 
 
 
 Experimental procedures 
 The experimental models were six specimens of 5 months old female Wistar rats 
(Rattus norvegicus) weighting 209 to 266 g. 
Before starting the surgical procedure, the anesthesia was induced with isoflurane 100% 
(IsoFlo
®
, veterinaria Esteve) by inhalation during approximately 5 minutes (Figure 4) and then 
they were anesthetized with an intraperitoneal injection of ketamine (Imalgene
®
, Merial) (0,2 
mg/100 g of body weight) plus xylasine 2% (Rompum
®
, Bayer) (0,065 mg/100 g) in a 1:1 ratio. 
The animals took approximately 10 minutes to reach the anesthetic level, which could be 
recognized and monitored by their slower and deeper breathing pattern. Whenever necessary the 
anesthesia was reinforced with a ¼ of the volume of the initial anesthetic dose. 
 
 
 
 
 
 
 
Fig. 3. Omeprazole powder 
Fig. 4. Equipment for the induction of anesthesia by inhalation with isoflurane 100% 
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The animals were submitted to a surgery at the experimental operation room at the 
Faculty of Dental Medicine, University of Porto, under sterile conditions, in which the surgical 
field was disinfected with a topical antiseptic povidone-iodine 10% (Betadine
®
, MEDA 
Pharma). A sagittal incision from the coronal suture until the lambdoidal suture was performed 
with a surgical scalpel blade #15 on a handle #3on the cranium skin and periosteum (Figure 5) 
and these were retracted until the osseous surface of both parietals was completely uncovered 
(Figures 6 and 7). 2 circular osseous defects with 3 mm of diameter (critical size defects) were 
made, one in each parietal bone, with a 4 mm bone carbide tapered bur on a low speed 
handpiece under constant sterile saline solution irrigation (NaCl 0,9%
®
, Braun), without injuring 
the dura mater or the sagittal sinus. Avoiding unnecessary trauma was a main concern during 
the whole surgery.  
 
 
 
 
 
 
 
 
 
The control group defects were made at the most posterior area of the left parietal bone 
(Figure 8), whereas the test defects were made at the most anterior zone of the right parietal 
(Figure 9), so that the defects would be as far as possible and their contents would not mix. The 
control defects (n = 6) were filled with Osteopatite
®
 granules and covered by a MES membrane 
previously wet and shaped with a sterile scissors, in order to make it more manageable and 
easier to adapt to the wound (Figure 10). The test defects (n = 6) were also filled with 
Osteopatite
®
 granules, as well as with 80 mg of omeprazole and were covered with the wet 
Fig. 5. Operators performing a sagittal incision on the rat„s cranium skin under sterile conditions 
Fig. 6, 7. Appearance of the cranium osseous surface after skin and periosteum retraction 
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MES membranes. The surgical wound was closed with interrupted silk 5-0 stitches (Surgisilk
®
, 
Sutures Ltd, U.K.) and was abundantly cleaned and disinfected with povidone-iodine 10% 
(Figure 11). The animals were housed in individual cages, so that injuries would not occur, until 
they woke up by themselves (Figure 12).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8. The control defect (arrow) was positioned at the most posterior area of the left parietal bone 
Fig. 9. The test defect (arrow) was located at the most anterior zone of the right parietal 
Fig. 10. Adaptation of the Osteopatite
®
 granules and the wet MES membrane to the defect 
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The animals were housed in a standard light–dark schedule, standard relative humidity, 
air pressure, air ventilation and temperature. Stock diet and tap water were available ad libitum 
(Figures 13 and 14). 8 weeks afterwards, the specimens were euthanized with an overdose of 
anesthetic (ketamine and xylzine), preceded by a sedation with isoflurane. A new sagittal 
incision was made, the skin and periosteum were retracted (Figure 15) and the parietal bones 
were removed from the cranium using a saw on a low speed handpiece under constant sterile 
saline solution irrigation (Figures 16 to 18). The samples were washed with saline solution, 
cataloged and stored in sterile plastic bottles for the fixation process in a formaldehyde solution 
4% in a phosphate buffer solution (pH 7,4) for 48 hours (Figures 21 to 35). 
 
 
 
 
Fig. 11. Suture of the incision with interrupted silk 5-0 stitches and disinfection of the wound with 
povidone-iodine 10% solution 
Fig. 12. The animals rested in individual cages during the anesthesia recovery period 
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Fig. 13,14. For 8 weeks the animals were housed in proper conditions of space, light, temperature, 
humidity, food and water 
Fig. 15. Upon the rats sacrifice, a new sagittal incision was performed to show the cranium surface 
Fig. 16. The bone was cut using a stainless steel saw on a low speed handpiece under saline solution 
refrigeration with a security distance in order to avoid the destruction of the study areas 
12 
 
 
 
 
 
 
 
 
 
 
Histological preparation 
 The histological procedures were performed at the Dental Anatomy Laboratory of the 
Faculty of Dental Medicine, University of Porto.  
 After the 48 hours fixation, the samples were dehydrated in a sequence of increasing 
concentrations of ethanol solutions, beginning with ethanol 70% for 48 hours at room 
temperature (20-25º C). Afterwards, the samples were placed successively in 70, 80, 90 and 
100% ethanol solutions for 48 hours each. The 100% ethanol solution was substituted 3 times 
for 48 to 48 hours. 
 During the inclusion procedure, each sample was placed in an individual sterile glass 
bottle containing 800 mL/L of methyl methacrylate (Methyl Methacrylate BDH
®
), 200 mL/L of 
Plastoid (Plastoid N
®
, Rohm Pharma) and 1 g/L of Perkadox (Akzo
®
 Chemicals Bv, 
Netherlands). The bottles were left unclosed, put in a vacuum equipment for 15 minutes, in 
order to remove every air bubbles, and then were hermetically closed and placed in a 37º C bath 
apparatus GFL (Gesellschaft fur Labortechnik GmbH, Germany) for 48 hours for the complete 
polymerization of the inclusion material. 
 The blocks where the samples were included were cut with a microtome (Accutom, 
Struers, Denmark) for non-decalcified tissues at 2500 rpm and low pressure, along with copious 
Fig. 17, 18. The surgical piece was carefully detached from the rest of the body, preventing its fracture 
Fig. 19, 20, 21. Plastic identified bottle with formaldehyde solution 4% in a phosphate buffer solution and 
the surgical pieces seen from the external and internal surfaces 
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lubrication and refrigeration to avoid mechanical or thermal alterations, in order to obtain 
sections with an average thickness of 150-200 μm. In order to reduce that width to 40 μm, the 
samples were polished (DAPS
®
, Struers, Denmark) with a series of discs of decreasing 
granulometry, starting with #1000 (P1000, 3M 734
®
, UK) and #1200 (P1200, 3M 714
®
, UK) 
and finishing with an ultra-thin grain (SF737, 3M
®
, UK). The final thickness was corroborated 
with a digital microtome (Digimatic Micrometer®, Mytotuyo, Japan). The samples were put in 
an equipment of ultrasound bath ULABO USRI (Julabo Labortechnick, Germany) for 10 
minutes, in order to remove the residues and impurities due to the cutting procedures. In some 
samples the cuts were longitudinal and in others were made transverse cuts. 
 The staining chosen was the Solochrome Cyanine R method, which differentiates 
osteoid from newly laid-down bone and older bone. The mineralized bone stains light blue, 
whereas the calcification front becomes dark blue. The osteoid bone is light red-orange, as well 
as the wide osteoid, which also has pale blue and orange bands. The nuclei become blue [25]. 
 The specimens were mounted on glass slides bonded with Permacol (Ind Permacol 
UV
®
, Adhesive 327/3, Permacol Ind. Netherlands), which is polymerized with ultraviolet light. 
In the same way, the glass coverslip was placed upon the specimen, avoiding the enclosure of 
air bubbles. The glass slides were appropriately identified and observed at the laboratory‟s 
optical microscope (Leica DMLB
®
, Wetzlar, Germany). The images were captured by a video 
camera coupled to the microscope and were visualized in a computer screen (LG W1943SB, LG 
Electronics
®
, Germany), through a specific software of image acquisition and analysis (Leica 
Lida, Leica Imaging Systems
®
, Cambridge, UK, 1996). The area of osseous defect which was 
filled with new bone was observed in each sample obtained. 
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Results 
 Just before the experimental surgeries, each specimen‟s weight was determined, as it is 
stated at Table 4.  
 
Table 4. The specimen‟s weight 
Specimen # Weight (g ± 1g) 
1 226 
2 213 
3 209 
4 231 
5 226 
6 266 
 
 The animals recovered from the surgeries and healed uneventfully until the end of the 
experiment, with exception to  the animals # 4 and 6, which wound healing took a little longer 
to close. However they did not show any signs of infection. 
Although the MES membranes were used upon all the defects to fix the granules as 
much as possible, in some samples these are spread all over the calvaria surface, especially 
those granules of bigger size (Figures 22a and b). 
 
 
 
 
 
 
 
 
Generally in this study, the use of Osteopatite
®
 microporous granules was benefic for 
bone regeneration, as it was noticed in all specimens and defects (tests or controls) that bone 
started developing inside or upon the microporosities (Figures 23a and b). Interestingly, the only 
granules that became completely osseointegrated were those of smaller size (Figures 24a and b), 
whereas the larger ones were only attached to the calcification front by one side. Some granules 
distant from the bone surface appeared surrounded by a calcification front of newly formed 
bone (Figures 25a and b). Frequently, adjacent granules became attached to each other through 
a b 
Fig. 22. Test critical size defect in which the membrane (arrows) is placed upon the defect area (asterisk) 
(a), but the granules, particularly those of wider diameter, are spread in a different place (b) (Solochrome 
Cyanine R stain; a and b: 2,5x) 
* 
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thin pink-orange bands of osteoid (Figure 26). The larger granules were usually surrounded by 
collagen fibers from the conjunctive tissue, which is precursor of the osteogenesis (Figure 27). 
 
 
 
a 
a 
b 
b 
a 
b 
Fig. 23. Bone formation cores (stained blue – arrows) inside the microporosities of the Osteopatite® 
granules, from the specimen # 2 test defect. (Solochrome Cyanine R stain; a: 10x; b: 20x) 
Fig. 24. Complete osseointegration of the smaller granules (arrows), whereas the larger ones only have 
one side contact with the calcification front (asterisk), from the specimen # 2 test defect. (Solochrome 
Cyanine R stain; a: 10x; b: 20x) 
Fig. 25. Granule (arrow) distant from the bone surface surrounded by a calcification front of newly 
formed bone (asterisk), from the specimen # 5 test defect (Solochrome Cyanine R stain; a: 10x; b: 20x) 
a 
a 
* 
* 
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Although in many cases the MES membranes were lost, moved or partially reabsorbed, 
it is clear that the membranes had some positive influence in the bone growth. Not only have 
they contributed to fix a bigger concentration of granules in the defects (Figure 28), but also 
promoted osseous regeneration themselves in the control defects (Figure 29). 
 
 
 
 
 
 
 
a 
Fig. 26. Thin pink-orange bands of osteoid (arrows) can be seen connecting adjacent granules. 
(Solochrome Cyanine R stain; 20x) 
Fig. 28. A group of Osteopatite
®
 granules underneath the MES membrane (arrows) (Solochrome 
Cyanine R stain; 2,5x) 
Fig. 27. Collagen fibers (arrow) precursors of osteogenesis surround the larger Osteopatite
®
 granules, 
from the specimen # 1 test defect (Solochrome Cyanine R stain; 20x) 
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Fig. 29. Bone formation (purple – asterisk) underneath the MES membrane (arrows) without the 
granule‟s influence. (Solochrome Cyanine R stain; 10x) 
* 
Fig. 30, 31, 32, 33. Histological images from specimen # 1. In the test group (left images) there are 
osseointegrated granules (arrow), while in the control group (right images) none were found. Although 
bone growth (asterisks) occurred in both cases, in the test group that growth is more pronounced 
(Solochrome Cyanine R stain; 30: 10x; 31: 20x; 32: 10x; 33: 10x) 
30 
31 
32 
33 
* 
* * 
36 
* 
34 
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Fig. 34, 35, 36, 37. Histological images from specimen # 2. In the test group (left images) there are 
osseointegrated granules (orange arrow), while in the control group (right images) none were found. 
There is bone growth (asterisks) in the test group while the control group only shows collagen fibers 
(black arrows). In figure 35 the collagen fibers are readily differentiating (red arrows) (Solochrome 
Cyanine R stain; 34: 20x; 35: 20x; 36: 10x; 37: 10x) 
34 
35 37 
* 
Fig. 38, 39, 40, 41. Histological images from specimen # 3. In the test group (left images) there are 
osseointegrated granules (orange arrows), while in the control group (right images) none were found. 
There is bone growth (asterisk) in both groups, despite in the control group most of it is collagen fibers 
(black arrows) (Solochrome Cyanine R stain; 38: 20x; 39: 20x; 40: 20x; 41: 10x) 
38 
39 
40 
41 
* 
* 
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Fig. 42, 43, 44, 45. Histological images from specimen # 4. In the test group (left images) there are 
osseointegrated granules (orange arrows), while in the control group (right images) none were found. 
There is bone growth (asterisk) in both groups. In the control group a few granules are about to start 
osseointegrating (black arrows) (Solochrome Cyanine R stain; 42: 20x; 43: 20x; 44: 10x; 45: 20x) 
* 
* 
* 
* 
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 Figures 30 to 53 show some features found in the test defects and in the control defects 
for each specimen. Generally, there is new bone formation equivalent in all animals and usually 
in all defect types. In all of the 6 animals at least two granules osseointegrated, as well as in all 
test defects. Despite this is more common in the test defects, some granules occasionally 
osseointegrated in the controls. 
It was not noticed the presence of any inflammatory cells in any of the samples.  
47 49 
Fig. 46, 47, 48, 49. Histological images from specimen # 5. In the test group (left images) there are 
osseointegrated granules (orange arrows), while in the control group (right images) none were found. 
There is bone growth (asterisk) in both groups. In the control group (49) a few granules are about to start 
osseointegrating (black arrows) (Solochrome Cyanine R stain; 46: 10x; 47: 10x; 48 20x; 49: 20x) 
* 
50 
51 
52 
53 
Fig. 50, 51, 52, 53. Histological images from specimen # 6. There are osseointegrated granules in both 
groups, despite in the test group (left images) there are more and larger osseointegrated granules (orange 
arrows), than in the control group (right images). There is bone growth (asterisk) in both groups. 
(Solochrome Cyanine R stain; 46: 10x; 47: 10x; 48 20x; 49: 20x) 
* 
* 
* 
* 
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Discussion 
 This preliminary study attempted to evaluate the topical effect of omeprazole powder on 
the prevention of bone resorption by the osteoclasts. This experiment was based in a paired 
sample design, in which in the same specimen there is a test and a control, making the results in 
each one directly comparable. In general, the test defects seem to present slightly better 
performances than the controls, however the results should be considered inconclusive, as the 
differences do not seem to be significant. 
3 mm critical size defects were made and filled with granules of Osteopatite
®
, which 
function as support structures for bone growth. The fact that it is a modified hydroxyapatite 
makes it chemically more similar to the natural inorganic component of bone, increasing its 
biological activity when compared to other types of hydroxyapatite granules [26]. These are also 
microporous enabling the ionic exchange from within the granules and modifying the pH, 
making it more alkaline, which favors the precipitation of Ca
2+
 from the medium, resulting in 
the formation of a natural hydroxyapatite film on the surface of the granules [21]. This fact is 
verified in the histological images where blue spots from the calcification front can be seen on 
the granules surface. Furthermore, Osteopatite
®
 granules do not undergo significant phenomena 
of degradation and resorption, which comprise beneficial features [21,27]. 
During the surgical procedures there were some difficulties in the placement and 
condensation of the Osteopatite
®
 granules to fill the defects because of their size when 
compared to the defects diameter. Corroborating this clinical observation, it seems from the 
histological analysis that the granules size (-20/+100 mesh) is too large for the diameter of the 
defects, because the majority of the osseointegrated granules are those of smaller dimensions. 
Besides, it is usually the largest granules that are displaced from the defects and are spread in 
the calvaria. Still, some experimental studies showed that if the granules are too small, there 
may be the risk of the granule‟s extensive phagocytosis by macrophages, especially for those 
which granulometry is inferior to 100 mesh [28]. Moreover, some of the defects surgically 
prepared were flatter, which may have influenced the displacement of the graft material. 
When compared to the amount of studies published on the other osteoclast PPIs cited 
previously, studies on omeprazole effect on bone resorption are scarce. Nevertheless, according 
to the literature, omeprazole would be expected to inhibit the osteoclasts function, either by 
systemic or local administration [19,29,30]. In the literature, there are not many clear references 
on the minimum or maximum quantity of omeprazole that should be administered, which is 
aggravated by the heterogeneity of the few published studies on this issue.  
One of the first studies made in this area was by Mattsson and Väänänen et al. (1991) 
[30], in vitro, where H
+
/K
+
ATPases were purified from the gastric mucosa and V-ATPases were 
prepared both from kidney medulla and from osteoclast-containing medullar bone. The aim was 
to evaluate and compare the potency of inhibition of omeprazole against bafilomycin A1 for 
both samples. As a result, omeprazole was much more potent in inhibiting H
+
/K
+
ATPases (IC50 
approximately 0,25 µM) than V-ATPases (IC50 approximately 200 µM). On the other hand, 
bafilomycin A1 was much more effective in inhibiting the V-ATPases (IC50 approximately 2 
nM) than H
+
/K
+
ATPases (IC50 approximately 50 µM). 
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In a study by Mizunashi et al. (1993) [19], the systemic effect of 20 mg per day of 
omeprazole in patients, who had a history of gastric ulcer, was evaluated through the urinary 
excretion of hydroxyproline and calcium, which decreased after omeprazole treatment in the 
study group, and increasing serum intact PTH, alkaline phosphatase, osteocalcin and tartrate-
resistant acid phosphatase in the same group, when compared to the control groups. These 
parameters variations may indict a reduction in the bone resorption. In the same study it is stated 
that the peak plasma concentrations of omeprazole obtained during clinical use are 
approximately 1-2 µM and that omeprazole inhibits the osteoclast V-ATPase in vitro only at 
high concentrations (≥100 µM) at pH 7,4. 
In a recent study by Sheraly et al. (2009) [29], pantoprazole or omeprazole were added 
to the chemical composition of calcium phosphate cements, which were implanted in rodent 
femora. In the first stage of the study, pantoprazole 0,5 mg/ml produced a delay in local 
osteoclast resorption, whilst this effect was not as evident using omeprazole at an equivalent 
dose (0,4 mg/ml). In a second stage higher doses of omeprazole (40 mg/ml, 100 times more 
concentrated) were used, which delayed the cement resorption. An important explanation for 
this phenomenon may be the fact that some studies have stated that omeprazole is generally 3 
times more instable in solution than pantoprazole, which makes it degrade faster and loose its 
therapeutic effect. Omeprazole stability is temperature (if stored at 4º C it is 3 times more stable 
than at 22º C), pH (at a pH of 5,1 the half-life of pantoprazole was 4,7 hours while that of 
omeprazole was 1,4 hours) and time dependent (the longer it remains in solution, the more 
likely it will protonate, become activated and degraded) [29]. Still, omeprazole conversion to its 
active form is slow at neutral pH, but the rate of transformation is rapidly increased as the pH is 
lowered. Inside the bone resorption lacunae pH varies between 3 and 4, which may potentiate 
the omeprazole effect [19].  
Summarizing, the only certain conclusion one can take from the literature is that in 
order to avoid osteoclast bone resorption, omeprazole must be present locally in large quantities. 
Therefore, we decided to try 80 mg of omeprazole powder, to make sure that it would be 
enough quantity. Nevertheless, during the surgical procedures it was quite difficult to 
condensate enough granules plus all of the volume of omeprazole in the defects. Further 
experiments will be needed to determine the most appropriated quantity of omeprazole. Another 
interesting trial could be using smaller Osteopatite
®
 granules (inferior to 100 mesh). Despite the 
fact that there is a risk of these being phagocytosed by macrophages [28], it is also true that the 
V-ATPases are present in the macrophages‟ membrane as well [3,5,6,11], therefore their 
function could also be inhibited by the omeprazole, which would stop them from destroying the 
granules [29]. 
Another advantage of using V-ATPases inhibitors, namely omeprazole, is that 
inhibition of the osteoclastic acidification leads to inhibition of bone resorption and, recently 
discovered, increasing of the osteoclasts lifespan [10]. Because the osteoclasts are not destroyed 
and are still present next to the bone matrix, the coupling cycle goes on without inhibiting bone 
formation. Consequently, there will be a stimulus for bone formation by the osteoblasts along 
with no bone resorption [1,10].  
Citing Sheraly et al. (2009) [29] and Rzeszutek et al. (2003) [12] once more, in both 
studies the drugs were solved in a proper solvent, dimethyl sulfoxide (DMSO), until the 
intended drug concentration was reached and this vehicle was added to the liquid phase of the 
calcium phosphate. This alternative method to deliver the drugs has the advantage of not being 
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almost right away absorbed by the organism by entering too soon in the blood circulation. 
However, as stated by the authors, further experiments are required before we can rule out 
DMSO effects on drug activity and eventual cell toxicity [29]. 
More recently other therapeutic targets for PPIs, namely omeprazole, are being studied. 
Resistance to antitumor agents is a major handicap for cure in cancer patients and some of these 
mechanisms may be related with increased acidification of extracellular compartments. Luciani 
et al. (2004) [31] made an experiment in which tumor cells derived from human melanomas, 
adenocarcinomas, and lymphomas were submitted to the action of a variety of gastric PPIs 
before treatment with cytotoxic agents. The inhibition of the V-ATPase activity induced a 
marked increase in the cytoplasmic retention of the cytotoxic drugs. In in vivo experiments, oral 
pretreatment with omeprazole was able to induce sensitivity of human solid tumors to cisplatin 
[31]. 
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Conclusions 
 Despite the fact that the results from the present preliminary study must be considered 
inconclusive, there is still some evidence that omeprazole can contribute to inhibition of 
resorption by the osteoclasts. Although not well explored yet, omeprazole presents some 
beneficial features against the other V-ATPases inihibitors, especially the fact that it is a very 
well known and secure drug with very few and rare adverse effects. Accordingly, further studies 
should be planned, in which new methodological approaches should be tried, such as 
incorporation of the drug in the graft material composition, use of smaller hydroxyapatite 
granules, determination of the most appropriated omeprazole doses, using larger animals and 
assessing the results in different time periods. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acknowledgments 
 The authors would like to thank to Laboratórios BIAL - Portela & Cª SA, S. Mamede 
do Coronado, Portugal, for the omeprazole generous offer. They would also like to thank to 
Professor Cavalheiro from INEB, Porto, Portugal for the Osteopatite
®
 and MES membranes 
generous offer. The authors thank the collaboration of Ana Mota as well for the histological 
procedures. 
  
25 
 
 
References 
 
[1] Sørensen MG, Henriksen K, Neutzsky-Wulff AV, Dziegiel MH, Karsdal MA. Diphyllin, a 
novel and naturally potent V-ATPase inhibitor, abrogates acidification of the osteoclastic 
resorption lacunae and bone resorption. J Bone Miner Res. 2007 Oct;22(10):1640-8. 
 
[2] Niikura K, Takeshita N, Takano M. A vacuolar ATPase inhibitor, FR167356, prevents bone 
resorption in ovariectomized rats with high potency and specificity: potential for clinical 
application. J Bone Miner Res. 2005 Sep;20(9):1579-88. 
 
[3] Keeling DJ, Herslöf M, Ryberg B, Sjögren S, Sölvell L. Vacuolar H(+)-ATPases. Targets 
for drug discovery? Ann N Y Acad Sci. 1997 Nov 3;834:600-8. 
 
[4] Xu J, Cheng T, Feng HT, Pavlos NJ, Zheng MH. Structure and function of V-ATPases in 
osteoclasts: potential therapeutic targets for the treatment of osteolysis. Histol Histopathol. 2007 
Apr;22(4):443-54. 
 
[5] Supanchart C, Kornak U. Ion channels and transporters in osteoclasts. Arch Biochem 
Biophys. 2008 May 15;473(2):161-5. 
 
[6] Yuan FL, Li X, Lu WG, Li CW, Li JP, Wang Y. The vacuolar ATPase in bone cells: a 
potential therapeutic target in osteoporosis. Mol Biol Rep. 2010 Feb 25. 
 
[7] Kajiya H, Okamoto F, Li JP, Nakao A, Okabe K. Expression of mouse osteoclast K-Cl Co-
transporter-1 and its role during bone resorption. J Bone Miner Res. 2006 Jul;21(7):984-92. 
 
[8] Yao G, Feng H, Cai Y, Qi W, Kong K. Characterization of vacuolar-ATPase and selective 
inhibition of vacuolar-H(+)-ATPase in osteoclasts. Biochem Biophys Res Commun. 2007 Jun 
15;357(4):821-7. 
 
[9] Henriksen K, Sørensen MG, Jensen VK, Dziegiel MH, Nosjean O, Karsdal MA. Ion 
transporters involved in acidification of the resorption lacuna in osteoclasts. Calcif Tissue Int. 
2008 Sep;83(3):230-42. 
 
[10] Karsdal MA, Henriksen K, Sørensen MG, Gram J, Schaller S, Dziegiel MH, et al. 
Acidification of the osteoclastic resorption compartment provides insight into the coupling of 
bone formation to bone resorption. Am J Pathol. 2005 Feb;166(2):467-76. 
 
[11] Gagliardi S, Nadler G, Consolandi E, Parini C, Morvan M, Legave MN, et al. 5-(5,6-
Dichloro-2-indolyl)-2-methoxy-2,4-pentadienamides: novel and selective inhibitors of the 
vacuolar H+-ATPase of osteoclasts with bone antiresorptive activity. J Med Chem. 1998 May 
7;41(10):1568-73. 
 
26 
 
[12] Rzeszutek K, Sarraf F, Davies JE. Proton pump inhibitors control osteoclastic resorption of 
calcium phosphate implants and stimulate increased local reparative bone growth. J Craniofac 
Surg. 2003 May;14(3):301-7. 
 
[13] Visentin L, Dodds RA, Valente M, Misiano P, Bradbeer JN, Oneta S, et al. A selective 
inhibitor of the osteoclastic V-H(+)-ATPase prevents bone loss in both 
thyroparathyroidectomized and ovariectomized rats. J Clin Invest. 2000 Jul;106(2):309-18. 
 
[14] Farina C, Gagliardi S, Nadler G, Morvan M, Parini C, Belfiore P, et al. Novel bone 
antiresorptive agents that selectively inhibit the osteoclast V-H+-ATPase. Farmaco. 2001 Jan-
Feb;56(1-2):113-6. 
 
[15] Farina C, Gagliardi S. Selective inhibition of osteoclast vacuolar H(+)-ATPase. Curr Pharm 
Des. 2002;8(23):2033-48. 
 
[16] Niikura K, Takeshita N, Chida N. A novel inhibitor of vacuolar ATPase, FR202126, 
prevents alveolar bone destruction in experimental periodontitis in rats. J Toxicol Sci. 2005 
Dec;30(4):297-304. 
 
[17] Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and 
pharmacokinetics. Eur J Clin Pharmacol. 2008 Oct;64(10):935-51. 
 
[18] Thomson AB, Sauve MD, Kassam N, Kamitakahara H. Safety of the long-term use of 
proton pump inhibitors. World J Gastroenterol. 2010 May 21;16(19):2323-30. 
 
[19] Mizunashi K, Furukawa Y, Katano K, Abe K. Effect of omeprazole, an inhibitor of 
H+,K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int. 1993 Jul;53(1):21-5. 
 
[20] Tuukkanen J, Väänänen HK. Omeprazole, a specific inhibitor of H+-K+-ATPase, inhibits 
bone resorption in vitro. Calcif Tissue Int. 1986 Feb;38(2):123-5. 
 
[21] Vasconcelos M, Afonso A, Branco R, Cavalheiro J. Guided bone regeneration using 
osteopatite granules and polytetrafluoroethylene membranes. J Mater Sci Mater Med. 1997 
Dec;8(12):815-8. 
 
[22] Tharanathan RN, Kittur FS. Chitin--the undisputed biomolecule of great potential. Crit Rev 
Food Sci Nutr. 2003;43(1):61-87. 
 
[23] Khor E, Lim LY. Implantable applications of chitin and chitosan. Biomaterials. 2003 
Jun;24(13):2339-49. 
 
[24] Mesquita P, Branco R, Afonso A, Vasconcelos M, Cavalheiro J. Mineralized membranes 
for bone regeneration. Key Engineering Materials. 2004 254-254:1091-1094. 
 
[25] Bancroft JD, Gamble M. Theory and Practice of Histological Techniques. 5th ed. London: 
Churchill Livingstone; 2002. p. 292. 
 
27 
 
[26] Cavalheiro J, Branco R, Vasconcelos M: Modified hydroxyapatite granules and plaster as 
binder: In vitro and clinical tests. In: Bonfield W, Hastings GW, Tanner KE, eds. Bioceramics, 
vol 4. London: Butterworth-Heinemann, 1991; 205-211. 
 
[27] Afonso A, Santos JD, Vasconcelos M, Branco R, Cavalheiro J. Granules of osteopatite and 
glass-reinforced hydroxyapatite implanted in rabbit tibiae. J. Mater. Sci.: Mater. Med. 1996; 7: 
507-510. 
 
[28] Carvalho GS, Pereira ML, Peres F, Vasconcelos M, Branco R, CavalheiroJ: Reacções in 
vitro e in vivo a diferentes dimensões de grânulos de hidroxiapatite modificada. Rev. Port, de 
Est. e Cir. Maxilofac. 1992; 32: 213-219. 
 
[29] Sheraly AR, Lickorish D, Sarraf F, Davies JE. Use of gastrointestinal proton pump 
inhibitors to regulate osteoclast-mediated resorption of calcium phosphate cements in vivo. Curr 
Drug Deliv. 2009 Apr;6(2):192-8. 
 
[30] Mattsson JP, Väänänen K, Wallmark B, Lorentzon P. Omeprazole and bafilomycin, two 
proton pump inhibitors: differentiation of their effects on gastric, kidney and bone H(+)-
translocating ATPases. Biochim Biophys Acta. 1991 Jun 18;1065(2):261-8. 
 
[31] Luciani F, Spada M, De Milito A, Molinari A, Rivoltini L, Montinaro A, et al. Effect of 
proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl 
Cancer Inst. 2004 Nov 17;96(22):1702-13. 
 
 
1 
 
Anexo 
 
Manuscript Submission at  
Journal of Materials Science: Materials in Medicine 
 
Instructions for Authors 
 
Title Page 
Title Page 
The title page should include: 
 The name(s) of the author(s) 
 A concise and informative title 
 The affiliation(s) and address(es) of the author(s) 
 The e-mail address, telephone and fax numbers of the corresponding author 
Abstract 
Please provide an abstract of 100 to 150 words. The abstract should not contain any undefined 
abbreviations or unspecified references. 
 
Text 
Text Formatting 
Manuscripts should be submitted in Word. 
 Use a normal, plain font (e.g., 10-point Times Roman) for text. 
 Use italics for emphasis. 
 Use the automatic page numbering function to number the pages. 
 Do not use field functions. 
 Use tab stops or other commands for indents, not the space bar. 
 Use the table function, not spreadsheets, to make tables. 
 Use the equation editor or MathType for equations. 
 Note: If you use Word 2007, do not create the equations with the default equation editor but 
use the Microsoft equation editor or MathType instead. 
 Save your file in doc format. Do not submit docx files. 
 
Word template 
Manuscripts with mathematical content can also be submitted in LaTeX. 
 
LaTeX macro package 
 
Headings 
Please use no more than three levels of displayed headings. 
 
Abbreviations 
 should be defined at first mention and used consistently thereafter. 
 
Footnotes 
Footnotes can be used to give additional information, which may include the citation of a reference 
included in the reference list. They should not consist solely of a reference citation, and they should never include 
the bibliographic details of a reference. They should also not contain any figures or tables. 
Footnotes to the text are numbered consecutively; those to tables should be indicated by superscript 
lower-case letters (or asterisks for significance values and other statistical data). Footnotes to the title or the 
authors of the article are not given reference symbols. 
Always use footnotes instead of endnotes. 
 
2 
 
Acknowledgments 
Acknowledgments of people, grants, funds, etc. should be placed in a separate section before the 
reference list. The names of funding organizations should be written in full. 
 
Scientific Style 
Please always use internationally accepted signs and symbols for units, SI units. 
 
References 
Citation 
Reference citations in the text should be identified by numbers in square brackets. Some examples: 
1. Negotiation research spans many disciplines [3]. 
2. This result was later contradicted by Becker and Seligman [5]. 
3. This effect has been widely studied [1-3, 7]. 
 
Reference list 
The list of references should only include works that are cited in the text and that have been published or 
accepted for publication. Personal communications and unpublished works should only be mentioned in the text. 
Do not use footnotes or endnotes as a substitute for a reference list. 
The entries in the list should be numbered consecutively. 
Journal article 
Smith JJ. The world of science. Am J Sci. 1999;36:234–5. 
 
Article by DOI 
Slifka MK, Whitton JL. Clinical implications of dysregulated cytokine production. J Mol Med. 2000; 
doi:10.1007/s001090000086 
 
Book 
Blenkinsopp A, Paxton P. Symptoms in the pharmacy: a guide to the management of common illness. 3rd 
ed. Oxford: Blackwell Science; 1998. 
 
Book chapter 
Wyllie AH, Kerr JFR, Currie AR. Cell death: the significance of apoptosis. In: Bourne GH, Danielli JF, Jeon 
KW, editors. International review of cytology. London: Academic; 1980. pp. 251–306. 
 
Online document 
Doe J. Title of subordinate document. In: The dictionary of substances and their effects. Royal Society of 
Chemistry. 1999. http://www.rsc.org/dose/title of subordinate document. Accessed 15 Jan 1999. 
 
Always use the standard abbreviation of a journal’s name according to the ISSN List of Title Word 
Abbreviations, see 
www.issn.org/2-22661-LTWA-online.php 
. 
For authors using EndNote, Springer provides an output style that supports the formatting of in-text 
citations and reference list. 
EndNote style 
 
Tables 
All tables are to be numbered using Arabic numerals. 
Tables should always be cited in text in consecutive numerical order. 
For each table, please supply a table caption (title) explaining the components of the table. 
Identify any previously published material by giving the original source in the form of a reference at the 
end of the table caption. 
Footnotes to tables should be indicated by superscript lower-case letters (or asterisks for significance 
values and other statistical data) and included beneath the table body. 
 
3 
 
Artwork 
For the best quality final product, it is highly recommended that you submit all of your artwork – 
photographs, line drawings, etc. – in an electronic format. Your art will then be produced to the highest standards 
with the greatest accuracy to detail. The published work will directly reflect the quality of the artwork provided. 
 
Electronic Figure Submission 
Supply all figures electronically. 
Indicate what graphics program was used to create the artwork. 
For vector graphics, the preferred format is EPS; for halftones, please use TIFF format. MS Office files are 
also acceptable. 
Vector graphics containing fonts must have the fonts embedded in the files. 
Name your figure files with "Fig" and the figure number, e.g., Fig1.eps. 
 
Line Art 
Definition: Black and white graphic with no shading. 
Do not use faint lines and/or lettering and check that all lines and lettering within the figures are legible at 
final size. 
All lines should be at least 0.1 mm (0.3 pt) wide. 
Scanned line drawings and line drawings in bitmap format should have a minimum resolution of 1200 dpi. 
Vector graphics containing fonts must have the fonts embedded in the files. 
 
Halftone Art 
Definition: Photographs, drawings, or paintings with fine shading, etc. 
If any magnification is used in the photographs, indicate this by using scale bars within the figures 
themselves. 
Halftones should have a minimum resolution of 300 dpi. 
 
Combination Art 
Definition: a combination of halftone and line art, e.g., halftones containing line drawing, extensive 
lettering, color diagrams, etc. 
Combination artwork should have a minimum resolution of 600 dpi. 
 
Color Art 
Color art is free of charge for online publication. 
If black and white will be shown in the print version, make sure that the main information will still be 
visible. Many colors are not distinguishable from one another when converted to black and white. A simple way to 
check this is to make a xerographic copy to see if the necessary distinctions between the different colors are still 
apparent. 
If the figures will be printed in black and white, do not refer to color in the captions. 
Color illustrations should be submitted as RGB (8 bits per channel). 
 
Figure Lettering 
To add lettering, it is best to use Helvetica or Arial (sans serif fonts). 
Keep lettering consistently sized throughout your final-sized artwork, usually about 2–3 mm (8–12 pt). 
Variance of type size within an illustration should be minimal, e.g., do not use 8-pt type on an axis and 20-
pt type for the axis label. 
Avoid effects such as shading, outline letters, etc. 
Do not include titles or captions within your illustrations. 
 
Figure Numbering 
All figures are to be numbered using Arabic numerals. 
Figures should always be cited in text in consecutive numerical order. 
Figure parts should be denoted by lowercase letters (a, b, c, etc.). 
4 
 
If an appendix appears in your article and it contains one or more figures, continue the consecutive 
numbering of the main text. Do not number the appendix figures, "A1, A2, A3, etc." Figures in online appendices 
(Electronic Supplementary Material) should, however, be numbered separately. 
 
Figure Captions 
Each figure should have a concise caption describing accurately what the figure depicts. Include the 
captions in the text file of the manuscript, not in the figure file. 
Figure captions begin with the term Fig. in bold type, followed by the figure number, also in bold type. 
No punctuation is to be included after the number, nor is any punctuation to be placed at the end of the 
caption. 
Identify all elements found in the figure in the figure caption; and use boxes, circles, etc., as coordinate 
points in graphs. 
Identify previously published material by giving the original source in the form of a reference citation at 
the end of the figure caption. 
 
Figure Placement and Size 
When preparing your figures, size figures to fit in the column width. 
For most journals the figures should be 39 mm, 84 mm, 129 mm, or 174 mm wide and not higher than 234 
mm. 
For books and book-sized journals, the figures should be 80 mm or 122 mm wide and not higher than 198 
mm. 
 
Permissions 
If you include figures that have already been published elsewhere, you must obtain permission from the 
copyright owner(s) for both the print and online format. Please be aware that some publishers do not grant 
electronic rights for free and that Springer will not be able to refund any costs that may have occurred to receive 
these permissions. In such cases, material from other sources should be used. 
 
Accessibility 
In order to give people of all abilities and disabilities access to the content of your figures, please make 
sure that 
All figures have descriptive captions (blind users could then use a text-to-speech software or a text-to-
Braille hardware) 
Patterns are used instead of or in addition to colors for conveying information (color-blind users would 
then be able to distinguish the visual elements) 
Any figure lettering has a contrast ratio of at least 4.5:1 
 
Electronic supplementary material 
Springer accepts electronic multimedia files (animations, movies, audio, etc.) and other supplementary 
files to be published online along with an article or a book chapter. This feature can add dimension to the author's 
article, as certain information cannot be printed or is more convenient in electronic form. 
Submission 
Supply all supplementary material in standard file formats. 
Please include in each file the following information: article title, journal name, author names; affiliation 
and e-mail address of the corresponding author. 
To accommodate user downloads, please keep in mind that larger-sized files may require very long 
download times and that some users may experience other problems during downloading. 
 
Audio, Video, and Animations 
Always use MPEG-1 (.mpg) format. 
 
Text and Presentations 
Submit your material in PDF format; .doc or .ppt files are not suitable for long-term viability. 
A collection of figures may also be combined in a PDF file. 
 
5 
 
Spreadsheets 
Spreadsheets should be converted to PDF if no interaction with the data is intended. 
If the readers should be encouraged to make their own calculations, spreadsheets should be submitted as 
.xls files (MS Excel). 
 
Specialized Formats 
Specialized format such as .pdb (chemical), .wrl (VRML), .nb (Mathematica notebook), and .tex can also be 
supplied. 
Collecting Multiple Files 
It is possible to collect multiple files in a .zip or .gz file. 
 
Numbering 
If supplying any supplementary material, the text must make specific mention of the material as a citation, 
similar to that of figures and tables. 
Refer to the supplementary files as “Online Resource”, e.g., "... as shown in the animation (Online 
Resource 3)", “... additional data are given in Online Resource 4”. 
Name the files consecutively, e.g. “ESM_3.mpg”, “ESM_4.pdf”. 
 
Captions 
For each supplementary material, please supply a concise caption describing the content of the file. 
 
Processing of supplementary files 
Electronic supplementary material will be published as received from the author without any conversion, 
editing, or reformatting. 
 
Accessibility 
In order to give people of all abilities and disabilities access to the content of your supplementary files, 
please make sure that 
The manuscript contains a descriptive caption for each supplementary material 
Video files do not contain anything that flashes more than three times per second (so that users prone to 
seizures caused by such effects are not put at risk) 
